In summary, we show that EDI3 is highly expressed in ER − HER2 + breast cancer, and when inhibited, leads to a significant reduction in viability and tumour growth, particularly in cells resistant to traditional HER2-targeting therapies. Here, GPCPD1 is linked to neoplasm.